According to FIGO 2023 staging of endometrial carcinoma, which new molecular subtype has been incorporated that changes staging independent of histological grade?
- A Microsatellite-instability-high (MSI-H) tumours are automatically Stage III
- B p53-abnormal tumours are classified as Stage II regardless of myometrial invasion
- C POLE-mutated (ultra-mutated) tumours are classified as Stage I regardless of other risk factors ✓
- D Copy-number-high tumours are always Stage IV
Correct answer: C. POLE-mutated (ultra-mutated) tumours are classified as Stage I regardless of other risk factors
Explanation
The revised FIGO 2023 staging integrates molecular profiling: POLE-mutated (POLEmut) endometrial carcinomas have an excellent prognosis and are classified as Stage I (with the suffix 'm1') regardless of other histological features, reflecting their ultra-favourable outcome. p53-abnormal tumours (TCGA copy-number high) carry poor prognosis and influence upstaging but are not automatically Stage IV. MSI-H and NSMP categories modulate risk stratification but do not have specific mandatory stage assignments.
Reference: Shaw's Textbook of Gynaecology, 17th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.